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Differential Regulation of Key Stages in Early Corneal
Wound Healing by TGF- Isoforms and Their Inhibitors
Louise M. Carrington,1,2 Julie Albon,1,2 Ian Anderson,3 Christina Kamma,1,2 and
Mike Boulton1,2
PURPOSE. Inhibition of TGF- reduces myofibroblast differenti-
ation and fibrosis in the cornea. Determining the actions of
distinct TGF- isoforms and their inhibitors during early cor-
neal wound healing is an essential step in guiding therapeutic
intervention.
METHODS. Bovine serum-free corneal cell and wounded organ
cultures were challenged with a range of concentrations of
TGF-1, -2, and -3; IL-10; and neutralizing human monoclonal
antibodies (mAbs) against TGF-1 (CAT-192) or -2, (CAT-152).
Cultures were assessed for re-epithelialization, proliferation
(cell counts and cresyl violet assay), morphology (histologic
examination), repopulation of the area under the wound, and
myofibroblast transformation (-smooth muscle actin) be-
tween 0 and 5 days.
RESULTS. TGF-1 delayed re-epithelialization, increased repopu-
lation of the stroma, increased keratocyte proliferation and was
the only isoform to promote myofibroblast differentiation. The
anti-TGF-1 mAb, CAT-192 promoted re-epithelialization and
reduced repopulation of the stroma. Exogenous TGF-3 had
little effect on re-epithelialization but reduced repopulation of
the stroma. IL-10 promoted corneal re-epithelialization at low
doses but inhibited this response at high doses. Stromal re-
population was prevented by all doses of IL-10. TGF-2 or the
anti-TGF-2 mAb, CAT-152 had little effect on any repair pa-
rameter.
CONCLUSIONS. The results confirm TGF-1 as the principal iso-
form in corneal wound healing and suggest that inhibition of
the action of TGF-1 can promote corneal wound healing.
Treatment with the anti-TGF-1 mAb CAT-192 accelerates cor-
neal re-epithelialization but reduces cell repopulation of the
stroma. The cytokines TGF-3 and IL-10 have opposing actions
to that of TGF-1. (Invest Ophthalmol Vis Sci. 2006;47:
1886–1894) DOI:10.1167/iovs.05-0635
TGF- has been established as a major regulator of woundhealing in most species and tissues, including the cor-
nea.1–3 To date, TGF-1 and -2 have been localized to both the
corneal epithelium and stroma, and both are constituents of
the tear fluid (Vesaluoma M, et al. IOVS 1996;37:ARVO Abstract
3912).4–9 Although mRNA of the 3 isoform has been isolated
from whole rat corneas at very low levels, its tissue location is
unclear, and the protein has yet to be detected in the non-
pathologic cornea.6,10
The TGF receptors RI and RII are located in epithelial,
stromal, and endothelial layers of the cornea.11–13 RI and RII
are present predominantly in the basal layer of corneal epithe-
lial cells, with receptor density increasing proximal to the
limbus in many species, including humans. The nonsignaling
TGF-RIII (-glycan receptor) has been located on both the
epithelium and endothelium in vivo, but appears to be absent
in keratocytes in vivo.11
As with many other growth factor signaling systems the
levels and spatial location of each component in the TGF-
system alters dramatically after a corneal wound. All three
isoforms are present in the corneal epithelium,4,14–16 and cor-
neal epithelial cells in culture release TGF-1 and -2.
17,18
TGF-2 is reported to be more strongly expressed than the
other two isoforms4 and throughout wound healing after PRK
and TGF-1, -2, and -3 are present in the corneal epitheli-
um.19 In stromal cells TGF- is upregulated,15 but isoforms
cannot be detected immunohistochemically until 2 days after
PRK, when rounded cells in the ablated area express all three
isoforms. TGF-1, -2, and -3 expression is delayed in spindle
shaped fibroblasts until 10 days after PRK. Expression of all
three isoforms returns to normal after 30 days. In addition,
levels of TGF-1 in the tear film increase dramatically (Vesa-
luoma M, et al. IOVS 1996;37:ARVO Abstract 3912). Of partic-
ular interest is the finding that topical administration of 1D11,
a TGF-1-, -2-, and -3-neutralizing antibody, to rabbit corneas
after PRK and lamellar keratectomy wounds, results in a reduc-
tion in the appearance of myofibroblasts, and substantially
decreases the incidence of haze in rabbits.2,3 Taken together,
this indicates a pivotal role for the TGF- system in corneal
maintenance and wound repair.
The TGF- superfamily is a structurally related group of
bioactive ubiquitous proteins with diverse and pleiotropic ac-
tivities. TGF-1 and -2 share 80% sequence homology but can
have opposite actions on biological processes such as prolifer-
ation, migration, and differentiation.1 The role of the various
isoforms of TGF- in corneal wound healing is not fully under-
stood, and therefore optimal treatment may rely on selective
inhibition of one or more TGF- isoforms. To manipulate the
cytokine environment of the healing cornea after either trauma
or elective surgery, it is necessary to understand the actions of
each TGF- isoform. It appears increasingly likely that the
events occurring within the earliest stages of corneal wound
healing alter prognosis.2,3 Herein, we describe the very differ-
ent actions of the three TGF- isoforms in early corneal wound-
healing events and their inhibition by human isoform-specific
neutralizing antibodies. The action of the cytokine IL-10, a
potential antagonist of TGF-, was also evaluated. The results
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of the study have been reported in part in abstract form
(Carrington LM, et al. IOVS 2001;42:ARVO Abstract 5018).
METHODS
Cell Culture
Nonactivated bovine keratocytes were cultured based on established
methods.3,20 In brief, the epithelial and endothelial layers were scraped
from the stroma which was incubated in 2 mg/mL collagenase (wt/vol
RPMI at 37°C; Invitrogen-Gibco, Paisley, Scotland, UK) overnight at
37°C. Isolated cells were plated at 1  104 cells/well (24-well plate) in
1 mL of serum-free RPMI containing nonessential amino acids (Invitro-
gen-Gibco), glutamine, antibiotics, amphotericin B. Cultures were
maintained in medium at 37°C in a standard 5% CO2-95% air atmo-
sphere for 48 hours, to allow attachment. Medium was replaced with
fresh medium containing 0.1, 1, or 10ng/mL TGF1, -2, or -3 or IL-10
(R&D, Abingdon, UK). Diluents were used as the control: 10 L of
phosphate buffered saline (PBS) containing 0.1% BSA and 0.01 M HCl
(TGF- isoform diluent) or 10 L of PBS containing 0.1% BSA (IL-10
diluent). All treatments were applied in triplicate for up to 5 days in
culture, and experiments were performed at least three times.
Organ Culture
Bovine corneas were centrally wounded with a 5-mm trephine, as
previously described,21 and the disc of epithelial-stromal tissue within
the wound was excised. Sterile, serum-free DMEM containing 1% agar
and 1% gelatin (BDH, Poole, UK) was used as a support, and serum-free
Trowell’s T8 medium (Invitrogen-Gibco) containing antibiotics, am-
photericin B, and glutamine was added to the dish to a level just below
the limbal region. Twice daily, 100 L of fresh serum-free T8 medium
was pipetted onto the surface of the cornea containing 1, 10, or 100
ng/mL TGF1, -2, or -3 or IL-10 (R&D Systems); or neutralizing mAb
against either active hTGF1 (CAT-192; 0.1 nM–10 M human IgG4;
Cambridge Antibody Technology, Cambridge, UK); or hTGF2 (CAT-
152; 10 M human IgG4; Cambridge Antibody Technology); or 10 L
of PBS containing 0.1% BSA (IL-10 and neutralizing antibody diluent) or
10 L of PBS containing 0.1% BSA, and 0.01 M HCl (TGF- isoform
diluent). Cultures were maintained in serum-free T8 medium for up to
5 days (n  6, per time, per treatment).
Re-epithelialization
Re-epithelialization was assessed as previously described,20,21 by using
captured macroimages of the wound area, where both the original
wound cut and the leading edge of the epithelium could be seen.
Re-epithelialization was expressed as the percentage of the original
wound area that was re-covered.
Morphologic Assessment of Epithelium
Wounded and unwounded corneas were fixed overnight in 10% neu-
tral buffered formalin (NBF), processed into wax. Seven-micrometer
sections were stained with Harris hematoxylin and eosin.
FIGURE 1. Percentage re-epithelialization of bovine corneal trephine wounds treated with 100 L of serum-free medium twice daily, containing
1% growth factor diluent (PBS0.1% BSAHCL) or 1, 10, or 100 ng/mL (a) TGF-1 and 10 M neutralizing mAb against hTGF-1, (b) TGF-2 and
10 M neutralizing mAb against hTGF-2, (c) TGF-3, or (d) IL-10. Each point represents the average of at least six corneas  SEM. Significant
differences were determined by Student’s t-test *P  0.05, **P  0.01.
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Assessment of Proliferation in Cell Culture Using
the Cresyl Violet Assay
Briefly, cells were fixed in 70% ethanol for 10 minutes at room tem-
perature and incubated with a 0.5% solution of cresyl violet (BDH) for
1 minute at room temperature. After washing with PBS, acetic acid
(33%, vol/vol ddH2O) was added to the wells to elute the dye. The
absorbance of the wells was read at 540 nm, with an ELISA reader, and
wells containing 33% acetic acid were used as a blank.
Stromal Cell Density beneath the Wound
Corneas were fixed in 10% NBF overnight and processed into wax.
Seven-micrometer sections were floated and incubated in 1 g/mL
bisbenzimide solution (Sigma-Aldrich, Poole, UK) for 10 minutes. Im-
ages of stained sections were captured, and the number of nuclei in the
area 100 m below the wound surface was analyzed (ImagePro Plus
software; Media Cybernetics, Silver Spring, MD).
Identification of Myofibroblasts
Cultured cells were fixed at 0, 1, 2, 3, 4, and 5 days after treatment in
1% paraformaldehyde for 5 minutes. Corneal organ cultures were snap
frozen in liquid nitrogen at 0, 1, 2, 3, and 5 days after treatment;
embedded in optimal cutting temperature compound (OCT); and sec-
tioned at 5-m intervals. Cultures and sections were pretreated with
0.1% Triton-X-100 for 20 minutes, incubated with a monoclonal anti-
smooth muscle actin antibody (Sigma-Aldrich) for 2 hours followed by
an Alexafluor 488-conjugated goat anti-mouse IgG (Invitrogen, Eugene,
OR) for 1 hour. Counterstaining of nuclei was obtained using bis-
benzimide solution incubation for 10 minutes. Cell cultures were also
costained with TRITC-conjugated phalloidin (5 g/mL in PBS; Sigma-
Aldrich) for 2 hours, to identify F-actin.
Statistical Analysis
Cell counts beneath the wound were compared by using the nonpara-
metric Mann-Whitney test. Proliferation was compared with unpaired,
two-way t-tests (Prism 3.0; GraphPad Software, San Diego, CA) Corneal
re-epithelialization was compared at each time point using either the
Kruskal-Wallis test (nonparametric ANOVA) with Dunn’s post test or
Mann-Whitney test, as appropriate. The rate of re-epithelialization was
assessed with a least-squares regression function of data between 24
and 48 hours and was expressed as the percentage of the wound area
re-epithelialized in 1 hour. The calculated EC50 for CAT-192 in the
re-epithelialization assay is indicated as the geometric mean with asso-
ciated 95% confidence limits.
RESULTS
Epithelial Wound Healing
Re-epithelialization followed a pattern similar to that previ-
ously described for this organ culture model.20,21 Epithelial
migration commenced within 12 hours after wounding, and,
by 72-hours, wounds had completely re-epithelialized for cor-
neas treated with medium alone or medium containing diluent
(Fig. 1). The rate of re-epithelialization was calculated to be
1.56%  0.07% h1.
Corneal re-epithelialization was differentially sensitive to
the three TGF- isoforms tested. TGF-1 was the most potent
inhibitor of re-epithelialization, inhibition was greatest at 100
ng/mL and halved the rate of re-epithelialization compared
with the control (0.71%  0.3% h1; P  0.05). The rate of
re-epithelialization for corneas treated with TGF-2 or -3 was
similar to that for the control (P 0.05), except that TGF-2 at
100 ng/mL caused a small delay in re-epithelialization at 72
hours (Figs. 1b, 1c).
Administration of CAT-192 (100 g/mL) resulted in an ac-
celerated rate of regrowth of the corneal epithelium such that
complete cover was established at 48 hours, corresponding to
a re-epithelialization rate of 2.11%  0.1% h1 (P  0.05
compared with the rate observed in vehicle-treated controls,
1.56%  0.07% h1, Fig. 1b). In a separate experiment the
concentration–response for CAT-192 was evaluated at a single
time point. CAT-192 (10 ng/mL–100 g/mL) applied to
wounded corneas resulted in a concentration-related enhance-
ment of corneal re-epithelialization measured at 40 hours, with
a calculated EC50 of 0.51 g/mL (0.23–1.10, 95% confidence
limits; n  12, Fig. 2). Neither CAT-152 or a null control IgG4
had a significant effect on the rate of re-epithelialization (Figs.
1b, 2)
IL-10 exhibited a pleiotropic effect on re-epithelialization
(Fig. 1d): 1 ng/mL had no effect, 10 ng/mL increased re-
epithelialization, and 100 ng/mL decreased re-epithelialization
(without apparent cytotoxicity using the trypan blue assay,
data not shown).
Epithelial Morphology
Epithelial morphology during re-epithelialization in control
corneas and those receiving diluent was similar to that previ-
ously described for this model20,21 and as depicted in Figure 3.
Initial rounding off and retraction of the epithelium from the
wound site at 4 hours was followed by migration onto the
denuded stroma at 12 hours with the leading edge of the
epithelium one cell deep, with no obvious stratification. Migra-
tion continued across the wound, with the leading edge of
epithelium increased to 3 to 4 cells and slight hypercellularity
at the original wound edge evident. By 72 hours, wound
closure had occurred with the epithelium at the closure site
thinner and less differentiated than the distal epithelium. After
5 days in culture the entire epithelium within the wound site
FIGURE 2. Dose response to CAT-192 during corneal re-epithelializa-
tion after an excisional trephine wound. The EC50 for CAT192 was 0.51
mg/mL (95% CI, 0.23–1.10; n  12). Data are expressed as the per-
centage change in re-epithelialization of the vehicle-treated control
group. Dotted lines: SEM of the vehicle control group data. A null IgG4
antibody control group (CAT-001, n  6) was included. Each point
represents the mean; vertical bars, SEM. The effect of the different
doses of CAT-192 was compared with control treatment using the
Kruskal-Wallis and Dunn tests. *P  0.01.
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exhibited good stratification, although slight thickening of the
epithelium within the wound area was common.
Morphologic differences were observed in corneas treated
with TGF-1 (Fig. 4). This included considerable thinning of
the epithelium in the wound site at all time points and was
more pronounced in the corneas receiving 100 ng/mL TGF-1
(Fig. 4b). Stratification of the epithelium migrating into the
wound was always evident, although the layers were thinner
than those in control corneas. By 120 hours, re-epithelialization
was complete, confirming the results of macroscopic image
analysis. Corneas treated with the anti-TGF-1 antibody CAT-
192 were similar to the control, although the epithelium ap-
peared slightly thinner (Figs. 4c, 4d).
Corneas receiving 1 ng/mL TGF-2 showed a retraction of
the wound edge that was not observed at higher concentra-
tions (Fig. 4e). Thinning of the epithelium was particularly
obvious at 100 ng/mL, especially at the interface between
wounded and unwounded stroma. By 48 hours in culture,
hypercellularity was evident at all TGF-2 concentrations, with
sparse populations of cell nuclei in the superficial layers and
loss of stratification correlated with increasing doses of TGF-2,
and at 100 ng/mL no obvious basal cells or superficial epithe-
lium were observed. Patches of acellularity were observed
within the epithelium (Fig. 4f). By 120 hours in culture all
wounds had closed, stratification of the epithelium was poor in
corneas treated with higher doses of TGF-2. Corneas receiving
a neutralizing antibody against TGF-2, CAT-152, showed mor-
phologic features similar to those observed in the control
corneas (Fig. 4g, 4h).
TGF-3, at all doses, showed considerable epithelial retrac-
tion from the wound edge at 4 hours and some cellular debris
(Fig. 4i). Morphology of the epithelium was reasonably normal
with some thinning toward the epithelial edge in corneas
treated with higher doses. By 24 hours, migration into the
wound had begun but was less advanced than in the control.
Hypercellularity and extreme thinning of the epithelium was
evident at the wound edge and stratification, as indicated by
lack of columnar cells in Fig 4j, became less evident with
increasing TGF-3 concentrations. By 120 hours in culture, the
epithelium had an increased thickness throughout the wound,
compared with the control (Fig. 4j).
IL-10 produced contrasting results, depending on dose. At 4
hours after wounding 1 ng/mL IL-10 showed neither retraction
nor migration, but the epithelium was thinned to three to four
cell layers, 10 ng/mL resulted in extreme thinning of the
leading edge of the epithelium and some retraction, whereas
100 ng/mL prompted migration of a very thin leading edge into
the wound area (Fig. 4k). At 24 and 48 hours, apart from
degree of migration, epithelial morphology was similar for all
three doses of IL-10. Stratification was not evident at the lead-
ing edge and hypercellularity was evident at the original
wound margin. By 72 hours, differentiation of cells was evident
but not confined to obvious layers, and basal cells were diffi-
cult to distinguish; 1-ng/mL-treated corneas demonstrated an
FIGURE 3. Epithelial morphology of
wounded corneas at various stages of
re-epithelialization. Unwounded bo-
vine corneas (a) contained 8 to 10
layers of cells within the epithelium
and 1 to 2 layers of desquamating,
flattened superficial epithelial cells
(black arrow). Corneas that had un-
dergone wounding with a trephine,
showed clean, sharply cut edges (b)
through the epithelium immediately
after wounding (black arrow), stro-
mal cutting was less defined (grey
arrow). Four hours after wounding
(c), the epithelium had retracted
from the cut edge of the stroma
(black arrow). As the epithelium mi-
grated across the denuded stroma
(d), the epithelium over the corner
of the original cut (black arrow) had
thinned to one to three layers deep,
whereas hypercellularity was often
observed within the wound’s edge
(white arrow). (e) The leading edge
of the epithelium had lost stratifica-
tion and become one to two cells
deep (black arrow). By 120 hours
(f), stratification of the healed epithe-
lium was evident with a slight thick-
ening compared with unwounded
corneas. Scale bar, 100 m.
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even epithelium within the wound area with some disruption
of the layering, whereas both 10 and 100 ng/mL produced
hypercellularity at the wound edges and a thinning of the
epithelium at the site of wound closure. At 120 hours, good
stratification was seen in corneas treated with all three doses
(Fig. 4l).
Keratocyte Proliferation
Keratocyte Cell Culture. Bovine keratocytes in serum-free
cell culture retained a stellate morphology similar to that seen
in vivo, forming a monolayer with interconnecting processes.
The initial seeding density of 1 104 cells per well, resulted in
a preconfluent culture; however, after 2 days in culture the
number of cells had increased to approximately 4  104 cells
per well and the keratocytes had extended long processes
toward each other, forming a network. The culture conditions
allowed low-level proliferation of keratocytes throughout the 5
days of experimentation (Fig. 5). Twenty-four hours after the
medium was changed, the number of keratocytes had in-
creased to 7.3  0.1  104 cells and continued to increase,
reaching 1.8  0.2  105 cells at 120 hours. Diluents had no
effect on keratocyte proliferation.
TGF-1 had no significant effect on keratocyte numbers at
either 1 or 10 ng/mL. However, at 0.1 ng/mL, TGF-1 more
than doubled the number of keratocytes at 120 hours of cul-
ture compared with the control (P  0.001; Fig. 5a). Other
isoforms had no effect on keratocyte proliferation at the con-
centrations tested (Fig. 5b, 5c).
All three concentrations of IL-10 stimulated keratocyte pro-
liferation in cell culture, with the cell number doubling com-
pared with the control (P  0.01l; Fig. 5d). The proliferative
response appeared to be initiated earlier in cultures treated
with 10 ng/mL IL-10.
Trephine-Wounded Corneas. The number of keratocytes
decreased to 56%  2% compared with unwounded control
corneas immediately after wounding, and a maximum reduc-
tion to 33%  1.5% was measured 4 hours after wounding.
Thereafter, the number of keratocytes gradually increased in
the wound area, and, by 120 hours, the number of cells be-
neath the wound had increased to 60%  7.5% of that in
unwounded corneas (Fig. 6).
The TGF- isoforms prompted very different repopulation
behavior. In agreement with the results from keratocyte cell
culture, the increase in cells under the wound was evident only
in corneas treated with the lowest concentration of TGF-1 (1
ng/mL), where, by 4 and 120 hours, the repopulation of cells
under the wound had increased from 33%  1.5% to 83% 
4.0%, respectively, of the unwounded control (Fig. 6a). In
contrast, the TGF-1 neutralizing mAb CAT-192 dramatically
decreased keratocyte numbers at all time points, compared
with the control (Fig. 6a). TGF-3 significantly decreased the
cell density under the wound at all concentrations tested (Fig.
6c). Similarly, addition of IL-10 decreased the number of cells
beneath the wound (Fig. 6d). Neither TGF-2 nor CAT-152 had
a significant effect on this response (Fig. 6b).
Myofibroblast Differentiation
Keratocytes cultures maintained in medium alone or plus di-
luent retained a stellate morphology and were -smooth mus-
cle actin negative. -Actin was located perinuclearly and
throughout the cytoplasm with no obvious stress fiber bundles
(Fig. 7a). Of all the factors tested in cell culture, only high-dose
TGF-1 prompted the differentiation of keratocytes into myo-
fibroblasts. Prominent stress fibers were obvious when cells
were stained with phalloidin, the cells lost their stellate shape
and elongated into spindles (Fig. 7b). More than half of the
cells staining positive for  smooth muscle actin which ap-
peared to be organized in bundles similar to the -actin fila-
ments.
Only very occasional cells, if any, were -smooth muscle
actin positive in control cornea organ cultures (Figs. 7e) with
FIGURE 4. Epithelial morphology after trephine wounding 4 (a, c, e,
g, i, k) and 120 (b, d, f, h, j, l) hours after treatment with 100 ng/mL
TGF-1 (a, b) or anti-TGF-1 (c, d); TGF-2 (e, 10 ng/mL; f, 1 ng/mL;
white arrow, an area apparently devoid of nuclei) or anti-TGF-2 (g,
h); 100 ng/mL TGF-3 (i, j; black arrow: cellular debris and retraction
of epithelium from the wound edge, white arrow); or IL-10 (k, 100
ng/mL; l, 10 ng/mL). Scale bar, 100 M.
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the exception of cells surrounding the lumen of blood vessels
in the corneal limbus (Figs. 7c, 7d). Very occasionally, isolated
cells were evident in the area under the wound after re-
epithelialization had occurred. Myofibroblasts became evident
in the stroma of corneas treated with 100 ng/mL of TGF-1
(Figs. 7f). These were located in the area directly under the
wound, within the upper 150 m of the stroma at the edge of
the wound face, with isolated cells (1% of stromal cells)
appearing at 72 hours after wounding. At 120 hours, the
number of -smooth muscle actin–positive cells had signifi-
cantly increased to 65.97%  13.57%, compared with control
corneas at the same time point (P  0.001). The stromal cells
of corneas treated with CAT-192 (anti-TGF-1), TGF-3 or IL-10
had no obvious -smooth muscle actin positive cells at any
time point.
DISCUSSION
We present evidence that TGF- isoforms differentially regu-
late several key events in early corneal wound healing. TGF-1
appeared to be the most active corneal isoform and was able to
delay re-epithelialization, increase proliferation of keratocytes,
enhance repopulation of the periwound area, and promote
myofibroblast transformation. Moreover, neutralization of en-
dogenously produced TGF-1 after treatment with the anti-
TGF-1 mAb, CAT-192, mediated an effect opposite the re-
sponse to exogenously added TGF-1. In contrast to the TGF-1
isoform, TGF-3 reduced the keratocyte repopulation of the
periwound area. TGF-2 or neutralization of TGF-2 with the
selective antibody CAT-152 had little effect on corneal wound
healing.
The effects of TGF-1 reported in this study concur with the
findings of other investigators in various species. First, TGF-1
was the only factor capable of inducing -smooth muscle actin
expression in stromal cells in cell and organ culture, a well-
documented phenomenon.3,22 Second, TGF-1 increased the
number of cells under the wound in wounded, organ-cultured
corneas, a finding in common with reports in the literature
involving rabbits.3 Third, a neutralizing antibody against the
active form of TGF-1, inhibits the slow repopulation of stro-
mal cells under the wound as previously shown after laser
keratectomy.23 Although not examined in this study, it is likely
that these events are, at least in part, mediated via connective
tissue growth factor.24
TGF-3 inhibited not only the repopulation of the stroma
observed in the control but also decreased the number of cells
below that seen at any time point in untreated corneas. Of
note, neutralizing TGF-3 had no effect, either on the number
of cells beneath the wound or the expression of laminin and
fibronectin in the cornea,23 and thus may act by inhibiting the
action of endogenous TGF-1 as occurs during wound healing
in the skin.25 TGF-3 knockout mice demonstrate scarring in
the fetal stage that does not occur after wounding in the
wild-type equivalent,26 and it appears that the ratio of TGF-1
to -3 is critical in determining the extent of fibrosis. Thus,
TGF-3 may be a candidate for therapeutic interventions, es-
pecially because it had no detrimental effect on corneal re-
epithelialization in this study.
Møller-Pedersen et al. 2 have reported that a pan neutraliz-
ing antibody (1D11) able to block all isoforms of TGF reduced
keratocyte activation and transformation and inhibited stromal
fibrosis in a rabbit model of PRK. However, in this rabbit
FIGURE 5. The effect of (a) TGF-1, (b) TGF-2, (c) TGF-3, and (d) IL-10 on the number of keratocytes in serum-free cell culture assessed using
the cresyl violet assay. Each point is the average of three experiments of triplicate wells. Error bars, SEM. Data were analyzed using the Students
t-test. *P  0.05; **P  0.01.
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model, the regrowth of the stroma was unaffected by pan
isoform neutralization with 1D11. Our results suggest that
while neutralizing TGF-1 may be important in preventing
fibrosis, the neutralization of TGF-3 may well be agonistic to
TGF-1 action. One may postulate that the best outcome (of a
single agent) would be selective neutralization of TGF-1, and
this could be achieved with the human monoclonal antibody
CAT-192. This approach may reduce fibrosis, keratocyte trans-
formation (and hence light-reflective keratocytes), as well as
repopulation of the stroma. Rapid re-epithelialization would
also limit additional stromal trauma. This approach would be
worthy of study in a model system such as experimental PRK.
IL-10 is classically regarded as a potent anti-inflammatory
cytokine and most studies into its function and effect have
centered on this premise. This study is the first to report the
effect of IL-10 on corneal wound healing. IL-10 was seen to
have a pleiotropic effect on the epithelium, increasing re-
epithelialization at 10 ng/mL, but suppressing wound coverage
at 100 ng/mL.
Sources for IL-10 include TH2 cells
27 and monocytes,28 both
of which should have no access to the cornea in nonpathologic
situations. IL-10 mRNA has been isolated from the corneas of
mice both before and after alkali burns29 and in humans during
corneal transplant surgery.30 Corneal epithelial cells are a likely
candidate, as the epithelia of other organs including skin pro-
duce IL-10.31–33 Previous studies have shown that IL-10 treat-
ment can reduce the migration of T-cells and neutrophils into
HSV-1-infected mouse corneas,34 reduce HLA-DR expression
on corneal cells and infiltrating leukocytes of human herpetic
stromal keratitis specimens,35 and decrease corneal opacifica-
tion in HSV-1-infected BALB/c mice.34,36 All of these in vivo
experiments were performed in the presence of a functioning
immune system and were characterized by immune cell infil-
tration of the cornea, which could have mediated the effects of
IL-10 on the corneal cells. The current study is therefore the
first to show that corneal cells, in the absence of lymphocytes,
can respond to IL-10 treatment and as such provides compel-
ling evidence that the cornea contains the IL-10 receptor.
Indeed, the upregulation of IL-10 Rc mRNA expression has
been identified in corneas after excimer laser injury.37
Little is known about the mechanism by which IL-10 regu-
lates epithelial cells and fibroblasts. IL-10 has been shown to
have antagonistic effects to the actions of TGF-,38 although
how this is achieved is unclear. IL-10 has been shown to
modulate extracellular matrix components by downregulating
type I collagen expression and upregulating collagenase and
stomelysin mRNA in human skin fibroblasts39; reducing con-
stitutive and transforming growth factor--stimulated, type I
collagen mRNA expression in human lung fibroblast cells40;
and downregulating the biosynthesis of fibrinogen in smooth
muscle cells,41 all of which may contribute to modulation of
fibrosis.
FIGURE 6. The effect of (a) TGF-1 and anti-TGF-1, (b) TGF-2 and anti-TGF-2, (c) TGF-3, and (d) IL-10 on the number of keratocytes beneath
a trephine wound in organ-cultured corneas between 0 and 120 hours after wounding. Points represent the average number of cells under the
wound as a percentage of the number at a comparable depth in that unwounded control. Each point is the average of six corneas per treatment
and error bars, SEM. Data were analyzed using the Kruskal-Wallis test (*P  0.05; **P  0.01). Significance symbols for 4-hour time points are not
shown due to lack of space.
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Our study confirms the primary role of the 1 isoform of
TGF during corneal wound healing. Furthermore, it identifies
IL-10 and TGF-3 as potential therapeutic regulators of corneal
repair and the prevention of fibrosis. It is also likely that early
application of treatment will be essential to minimize adverse
healing and optimize repair. A postoperative indication such as
corneal refractive surgery could be benefited by this type of
biological therapy.
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